TREATMENT FOR THE DYSFUNCTION OF MEIBOMIAL GLANDS

Patent number:

202230503

Comunidad de Madrid.svg
No items found.

The present invention relates to a substantially pure population of mesenchymal stem cells to use them in the prophylactic and/or therapeutic treatment for Meibomian gland dysfunction.

Countries:
Spain
Regions:
Community of Madrid
Centers:
UNIVERSIDAD AUTONOMA DE MADRID, FUNDACION INST DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Other entities:
Sectors:
Health
Subsectors:
TRL Level:
TRL 4 – technology validated in lab
BRL Level:
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

Although there are some current treatments for MGD, there is also an unmet medical need to find alternative treatments that are effective and without side effects. The invention shows that mesenchymal stem cells, mainly those derived from adipose tissue and used allogeneically, are a safe and feasible therapy for the treatment of MGD. Specifically, it shows that patients with MGD-related disease show clear improvements in ocular pain and epithelial defect, visual acuity, and corneal opacity.

Comments

Other related patents

Health

IN VITRO METHOD FOR SCREENING, DIAGNOSIS AND/OR PROGNOSIS OF COLORECTAL CANCER

Countries
Spain
Know more
Health
New & Sustainable Materials

A 3D Printable Anthropomorphic Phantom for Mimicking the Dielectric Properties of Mammary Tissues and use thereof

Countries
Spain
Know more
Health

NEW SENSORS FOR MULTIANALYTE DETECTION

Countries
Spain
Know more
Get back to patents directory